Floatz logo

pf-08046876

Esophageal Adenocarcinoma

PfizerPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Esophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
I-Mab Biopharma US Limited
Phase 3BB
Cetuximab
BeOne Medicines
Phase 2B
Capecitabine
I-Mab Biopharma US Limited
Phase 3B
Tislelizumab
BeOne Medicines
Phase 3B
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3B

View all 50 →

Same molecule, other indications

pf-08046876 is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
Advanced/Metastatic Solid TumorsDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →